a standing ovation for daraxonrasib at asco. over 40k oncologists, entrepreneurs, investors, and patient advocates together celebrating revmed's breakthru in the fight against pancreatic cancer. u never forget these moments. it's what innovation is all about.

a standing ovation for daraxonrasib at asco. over 40k oncologists, entrepreneurs, investors, and patient advocates together celebrating revmed's breakthru in the fight against pancreatic cancer. u never forget these moments. it's what innovation is all about.

An amazing breakthrough by $RVMD that should see the name rally not just on pancreatic cancer TAM but on the “copy paste” potential for them to use RAS being a druggable target for further things beyond pancreatic cancer. We detailed this dynamic in our 26 Trades for 2026. https://t.co/UVL3uVmc0G

一款由 $RVMD 开发的实验性药物daraxonrasib，被证明对一种侵袭性强且极难治疗的胰腺肿瘤具有广泛疗效。 早在四月就披露，该药物在一项三期临床试验中，相比标准化疗，几乎将患者生存期提高了一倍。 周日，在美国临床肿瘤学会（ASCO）年会上，研究者公布了更为完整的细节，专家形容这些结果是“前所未有”“改写治疗格局”。 在 ASCO 公布的数据中，所有接受该药物治疗的患者，中位总生存期达到 13.2 个月。相比之下，接受化疗且带有 RAS G12 突变的患者，中位生存期为 6.6 个月；而如果看所有接受化疗治疗的患者，这一数字为 6.7 个月，差异接近翻倍。 FDA 已经批准扩大使